Derbyshire Medicines Management and Clinical Policies
RED: NICE TA878 - Treatment of symptomatic adults and adolescents (aged ≥12 years and weighing ≥40kg) with acute COVID-19 infection who do not require oxygen supplementation and who are at increased risk of progressing to severe COVID infection only if nirmatrelvir plus ritonavir (Paxlovid) is contraindicated or unsuitable. (Decision date - April 2023 2022)
Sotrovimab is restricted for supply via secondary care (CMDU). Further information on mMabs can be found here.
